Breaking News Bar

Business News and Information

Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading

The clinical-stage biopharmaceutical company, which has its U.S. office near the Texas Medical Center, focuses on the discovery and development of T cell redirecting cancer immunotherapies.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear